1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Data May Facilitate Closing Of Pfizer Merger

 
• By Joseph Haas

With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval.

Antibody-drug conjugate
Seagen/Astellas's Padcev might now be appropriate treatment in more bladder cancer patients • Source: Shutterstock

Seagen Inc. and Astellas Pharma, Inc.’s antibody-drug conjugate Padcev met both overall and progression-free survival endpoints in a top-line readout from the Phase III EV-302/KEYNOTE-A39 trial testing the ADC in combination with Merck & Co., Inc.’s anti-PD-1 stalwart Keytruda, results that analysts said could increase Padcev’s addressable market in urothelial cancer to the $5bn range and de-risk the expected close of Seagen’s merger with Pfizer Inc.

Although the companies did not provide numerical data, saying full details will be disclosed at an upcoming medical conference, the Padcev/Keytruda regimen tested against chemotherapy hit the OS and PFS...

Key Takeaways

  • Seagen and Astellas unveiled data that may lead to a full approval for the combination of Padcev and Keytruda in advanced urothelial cancer.

  • Study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.